tradingkey.logo

Quantum BioPharma Ltd

QNTM
查看详细走势图
4.200USD
+0.280+7.14%
收盘 02/06, 16:00美东报价延迟15分钟
16.03M总市值
亏损市盈率 TTM

Quantum BioPharma Ltd

4.200
+0.280+7.14%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+7.14%

5天

-8.30%

1月

-42.15%

6月

-85.62%

今年开始到现在

-42.47%

1年

-62.90%

查看详细走势图

TradingKey Quantum BioPharma Ltd股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Quantum BioPharma Ltd当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名166/392位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价40.25。中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Quantum BioPharma Ltd评分

相关信息

行业排名
166 / 392
全市场排名
317 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Quantum BioPharma Ltd亮点

亮点风险
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
估值高估
公司最新PE估值-0.47,处于3年历史高位
机构加仓
最新机构持股1.11M股,环比增加13.26%

分析师目标

根据 2 位分析师
买入
评级
40.250
目标均价
+906.25%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Quantum BioPharma Ltd新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Quantum BioPharma Ltd简介

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
公司代码QNTM
公司Quantum BioPharma Ltd
CEOKotra (Lakshmi P)
网址https://www.quantumbiopharma.com/
KeyAI